Please note, this OEL/ADE monograph also applies to camostat mesylatem (CAS RN XXX). Camostat is an orally bioavailable, synthetic serine protease inhibitor, with antiinflammatory, antifibrotic, and potential antiviral activities. Camostat mesylate, also known as FOY-305, was first approved in Japan in January 2006 (3). Camostat mesylate is indicated in Japan to treat acute symptoms of chronic pancreatitis and postoperative reflux esophagitis. Camostat mesylate is also being investigated as a potential treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) coronavirus disease 2019 (COVID-19) in ambulatory adult patients.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Camostat, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.